Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
The company's comments Friday come after the White House said U.S.Trade Representative Robert Lighthizer will "address the threatened impairment" of national security from...Autosread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
Some analysts see streaming services like Netflix becoming hindered by one of the things that made them so popular in the first place — binge watching.Entertainmentread more
Apple CEO Tim Cook was the commencement speaker at Tulane University Saturday. In his speech, the tech executive focused on the importance of addressing climate change and...Power Playersread more
There is a shortfall of cybersecurity workers that could reach as high as 3.5 million unfilled roles by 2021. A start-up called Synack provides crowdsourced security, and...CNBC Disruptor 50read more
Yardeni Research's Edward Yardeni recommends investing in U.S. companies with exposure to China.Trading Nationread more
CNBC and SurveyMonkey's latest small business optimism index echoes that sentiment, finding 52 percent of small businesses say it's harder to find workers today than it was a...US Economyread more
CNBC combed through Wall Street research over the last week to see which stocks analysts say have the best risk-reward.Marketsread more
Western Union is not panicking, but the delivery of money around the world is being upended, says CEO of upstart TransferWise. It broke into the $689 billion remittances...CNBC Disruptor 50read more
Catalent said on Monday it would buy privately held gene therapy-focused Paragon Bioservices in an all-cash deal for $1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments.
Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing and manufacturing products such as complex biopharmaceuticals for its clients.
Catalent also develops drugs for other companies and does business in Asia, Europe, and North and South America.
The deal follows other multi-billion dollar deals as drug companies have been aggressively moving into the potentially $40 billion addressable market for gene therapy, where treatments for rare, genetic diseases command some of the highest prices.
In Februray, Swiss drugmaker Roche agreed to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion, while Novartis purchased U.S.-based Avexis for $8.7 billion last year.
Catalent expects the transaction to add to its adjusted earnings in the second full fiscal year after closing.
The company said it will fund the deal with proceeds from a $650 million incremental term loan and issuance of $650 million of a new series of convertible preferred stock.
After the deal closes, Paragon will be led by its Chief Executive Officer Pete Buzy.
The Wall Street Journal reported on Sunday that Catalent had agreed to buy Paragon.